Brian Yang
Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Latest From Brian Yang
Regulatory, Security Concerns Force Wuxi NextCODE To Cut China Ties
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
US Revocation Of Hong Kong Special Status To Rain On Biotech IPO Parade?
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
CanSino Coronavirus Vaccine Approved For Military Use In China
The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.
New China Indications For Merck, Novo, Boehringer Drugs
China continues with a post-coronavirus approvals rush, granting additional indications to Merck's Keytruda, BI's Ofev and Novo Nordisk's Norditropin.
Seizing The Day: How Coronavirus Breaks Then Makes Vaccine Makers In China
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
China Inc. Eyes Gene Therapy In Post-Coronavirus Growth Trajectory
Eyeing a largely untapped treatment area and huge patient pool, biotechs in China are leaping into the gene therapy foray despite the lack of a distinct regulatory pathway or reimbursement of the highly costly treatments.